发布求助
文献互助 智能选刊 最新文献

Cancer chemotherapy reports最新文献

筛选
英文 中文
Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect. 具有多物种肾毒性作用的抗肿瘤药物cytembena (NSC-104801)的毒理学研究。
Cancer chemotherapy reports Pub Date : 1975-11-01
E J Gralla, G L Coleman, G W Osbaldiston, M Kashgarian, A M Jonas
{"title":"Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.","authors":"E J Gralla,&nbsp;G L Coleman,&nbsp;G W Osbaldiston,&nbsp;M Kashgarian,&nbsp;A M Jonas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The toxic effects of cytembena in beagle dogs and rhesus monkeys were investigated with the drug given as single or daily iv injections in doses ranging from 12.5 to 200 mg/kg/day to dogs and 6.25 to 50 mg/kg/day to monkeys. Renal tubular damage was a major drug- and dose-related finding in both species and was clinically indicated by an accompanying uremia, elevated serum creatinine, and proteinuria. In the kidney, the primary lesion was cellular necrosis and desquamation of the distal tubular epithelium in animals given the lowest toxic doses. More severe but similar histologic changes produced by this drug were further characterized by single dose studies in mice which showed renal mitochondrial swelling and disruption plus generalized cell swelling as progressive, subcellular developments which were well established 24 hours after treatment. Cellular regeneration in the renal tubular epithelium was found in dogs and monkeys retained 6 weeks for observation after treatment, although functional recovery was inconsistent. A toxic effect to lymphoid tissue was an additional finding which is described.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1071-81"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12003725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose cyclophosphamide (NSC-26271) for recurrent or progressive ovarian adenocarcinoma. 高剂量环磷酰胺(NSC-26271)用于复发性或进展性卵巢腺癌。
Cancer chemotherapy reports Pub Date : 1975-11-01
M S Piver, J J Barlow, W S Chung
{"title":"High-dose cyclophosphamide (NSC-26271) for recurrent or progressive ovarian adenocarcinoma.","authors":"M S Piver,&nbsp;J J Barlow,&nbsp;W S Chung","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1157-8"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study. 阿霉素(NSC-123127)加5-氟尿嘧啶(NSC-19893):一项I期研究。
Cancer chemotherapy reports Pub Date : 1975-11-01
B L Tranum, R L Stephens, D E Lehane, B Hoogstraten, M Lane, A Haut
{"title":"Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study.","authors":"B L Tranum,&nbsp;R L Stephens,&nbsp;D E Lehane,&nbsp;B Hoogstraten,&nbsp;M Lane,&nbsp;A Haut","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1163-5"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma. 阿霉素(NSC-123127)在转移性黑色素瘤患者中的II期研究。
Cancer chemotherapy reports Pub Date : 1975-11-01
W J Sieper, M J Mastrangelo, R E Belle
{"title":"Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma.","authors":"W J Sieper,&nbsp;M J Mastrangelo,&nbsp;R E Belle","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1181-2"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Cardiotoxicity of 5-fluorouracil (NSC-19893) 信:5-氟尿嘧啶的心脏毒性(NSC-19893)
Cancer chemotherapy reports Pub Date : 1975-11-01
A Roth, K Kolaric, S Popovic
{"title":"Letter: Cardiotoxicity of 5-fluorouracil (NSC-19893)","authors":"A Roth,&nbsp;K Kolaric,&nbsp;S Popovic","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1051-2"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12398676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemotherapy of transplanted adenocarcinomas of the colon in mice. 小鼠移植结肠腺癌的化疗。
Cancer chemotherapy reports Pub Date : 1975-11-01
J A Double, C R Ball
{"title":"Chemotherapy of transplanted adenocarcinomas of the colon in mice.","authors":"J A Double,&nbsp;C R Ball","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Transplantable adenocarcinomas of the colon in mice have been developed from primary tumors induced by 1,2-dimethylhydrazine. Two such transplant lines, MAC-13 and MAC-15, have been used to assess the possible value of this type of tumor in chemotherapy screening. A protocol has been established and 11 standard drugs were tested against the two lines. Both tumors show sensitivity which is remarkably similar to that of human large bowel cancer, and MAC-13 would have correctly predicted the activity in man for ten of the 11 drugs. Quantitatively, CCNU, methyl-CCNU, and cyclophamide were the most effective drugs. A comparison of the predictive efficiencies of L1210 leukemia, B16 melanoma, and these new tumors as screening systems for colorectal cancer is made and discussed.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1083-9"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12398678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trial of hydrazine sulfate (NSC-150014) in patients with cancer. 硫酸肼(NSC-150014)在癌症患者中的临床试验。
Cancer chemotherapy reports Pub Date : 1975-11-01
M Ochoa, R E Wittes, I H Krakoff
{"title":"Trial of hydrazine sulfate (NSC-150014) in patients with cancer.","authors":"M Ochoa,&nbsp;R E Wittes,&nbsp;I H Krakoff","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1151-4"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure. 塔利卡平(NAC-68075)是一种新型结构的植物生物碱。
Cancer chemotherapy reports Pub Date : 1975-09-01
P J Creaven, M H Cohen, O S Selawry, F Tejada, L E Broder
{"title":"Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure.","authors":"P J Creaven,&nbsp;M H Cohen,&nbsp;O S Selawry,&nbsp;F Tejada,&nbsp;L E Broder","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An initial clinical trial of daily and weekly X 6 ihtravenous infusions of thalicarpine, a plant alkaloid of novel structure, was carried out in 36 patients. Twenty-eight patients received 33 courses of single-dose administration at doses of 200-1900 mg/m2. At the maximum tolerable dose of 1400 mg/m2, toxic effects included arm pain (nine or ten), central nervous system depression (seven of ten), nausea and vomiting (two of ten), hypotension (two of ten), hypertension (two of ten), arrhythmia (premature ventricular contractions) (one of ten), and electrocardiographic changes (mainly T-wave flattening) (five of ten). At the maximum tolerable dose for weekly administration, 1100 mg/m2/week X 6, arm pain was seen in seven of eight, central nervous system depression in three of eight, hypotension in one of eight, and electrocardiographic changes in three of eight. The recommended dose for phase II trials is 1100 mg/m2/week by a 2-hour intravenous infusion.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 5","pages":"1001-6"},"PeriodicalIF":0.0,"publicationDate":"1975-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11348210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of solid tumors and lymphomas with methyl-CCNU (NSC-95441): a phase II study. 甲基- ccnu (NSC-95441)治疗实体瘤和淋巴瘤:一项II期研究
Cancer chemotherapy reports Pub Date : 1975-09-01
D Firat, G Tekuzman
{"title":"Treatment of solid tumors and lymphomas with methyl-CCNU (NSC-95441): a phase II study.","authors":"D Firat,&nbsp;G Tekuzman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 5","pages":"1021-3"},"PeriodicalIF":0.0,"publicationDate":"1975-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12286394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056). 苦杏仁苷MF (NSC-15780)单用及联合β -葡萄糖苷酶(NSC-128056)抗肿瘤活性的实验研究。
Cancer chemotherapy reports Pub Date : 1975-09-01
W R Laster, F M Schabel
{"title":"Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056).","authors":"W R Laster,&nbsp;F M Schabel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Amygdalin MF was evaluated alone and in combination with an activating agent, beta-glucosidase, against three transplantable rodent tumors; Ridgway osteogenic sarcoma, Lewis lung carcinoma, and P388 leukemia. In dose-response studies up to the LD20 in normal mice, amygdalin MF alone did not demonstrate significant antitumor activity against any of these three tumor systems. Similarly, at doses not exceeding the LD10 in normal mice, amygdalin MF plus beta-glucosidase did not demonstrate antitumour activity against any of these three tumor systems. Potentiation of the lethal toxicity of amygdalin MF by beta-glucosidase was observed in all studies where the two agents were given in simultaneous combination.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 5","pages":"951-65"},"PeriodicalIF":0.0,"publicationDate":"1975-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12241304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书